English ministers veto Alexion's ultra orphan Soliris

English health ministers have rejected orphan drugs advisor, AGNSS' recommendation endorsing Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS). The ministers want more advice on the drug's affordability and are sending it for review by NICE, despite concerns that the health technology appraisal institute's current methods are unsuitable for drugs for rare conditions.